A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO

PHASE3CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Central Retinal Vein OcclusionMacular Edema
Interventions
DRUG

ranibizumab

0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.

DRUG

ranibizumab

Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.

Trial Locations (4)

0264

Bettina Kinge, Retinaklinikken Aleris, Oslo

Unknown

Ingar Stene Johansen, Oslo

Vegard Forsaa, Stavanger

Kristian Fossen, Tromsø

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Aleris Helse

OTHER